(Q43612115)

25 November 2017

Successful thalidomide treatment of severe infantile Behçet disease (English)

1 reference

25 November 2017

0 references

0 references

Brik R

1

1 reference

PubMed ID

11358558

25 November 2017

Shamali H

series ordinal

2

1 reference

PubMed ID

11358558

25 November 2017

Bergman R

series ordinal

3

1 reference

25 November 2017

1 March 2001

1 reference

25 November 2017

Pediatric Dermatology

1 reference

25 November 2017

18

1 reference

25 November 2017

2

1 reference

25 November 2017

143-145

1 reference

Pediatric onset of Behçet's syndrome with myositis: case report and literature review illustrating unusual features

25 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

Development of polyneuropathy during thalidomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

Thalidomide Responsiveness in an Infant With Behçet's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1470.2001.018002143.X

10.1046/J.1525-1470.2001.018002143.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11358558